CAMBRIDGE, Mass., Sept. 01, 2026 (GLOBE NEWSWIRE) -- Akebia Therapeutics ® , Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney...
CAMBRIDGE, Mass., Sept. 01, 2026 (GLOBE NEWSWIRE) -- Akebia Therapeutics ® , Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease,...
Akebia Therapeutics: Q2 Earnings Snapshot
Q2 2026 Vafseo ® (vadadustat) net product revenues grew to $21.3 million ; more than 10,500 p atients now on therapy Advancement of rare kidney disease pipeline continues with initiation...
Q2 2026 Vafseo® (vadadustat) net product revenues grew to $21.3 million; more than 10,500 patients now on therapy
Barchart Research What to Expect from AKBA Earnings AKBA Generated August 4, 2026 Current Price $1.3200 EPS Estimate $$-0.03 Consensus Rating Strong Buy Average Move 10.38% Akebia Therapeutics Enters Earnings...
CAMBRIDGE, Mass., Aug. 03, 2026 (GLOBE NEWSWIRE) -- Akebia Therapeutics ® , Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease,...
CAMBRIDGE, Mass., Aug. 03, 2026 (GLOBE NEWSWIRE) -- Akebia Therapeutics®, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better...
CAMBRIDGE, Mass., Aug. 03, 2026 (GLOBE NEWSWIRE) -- Akebia Therapeutics ® , Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney...
The open-label Phase 2 trial will evaluate ebribafusp for the treatment of IgA nephropathy, lupus nephritis and C3 glomerulopathy